🔗 Share this article World Health Organization Issues Concern Over Acute Lack of Obesity Injections Less than 10% of patients who could benefit from GLP-1 drugs like Wegovy have access to them, warns the World Health Organization as it publishes its initial guidance on the therapies. Given over a billion individuals worldwide currently obese, it is advocating for increased and just availability to these injectable treatments. According to projections, over two billion will be obese by 2030 if no action is taken. "Our new guidelines acknowledges that excess weight is a chronic disease that can be managed with thorough and ongoing treatment," remarked its chief Tedros Adhanom Ghebreyesus. High costs, insufficient output, and supply-chain constraints are major hurdles to universal availability to the treatments that can help people shift substantial weight, explains the body. Skinny Jab Supply Crisis Even under the present most favorable outlook, the production of these medications might only reach about 100 million people – fewer than 10% of those who need them, as stated by the WHO. The advice urges nations and manufacturers to expand access, by strategies including patent sharing. The intellectual property rights on semaglutide – the primary component of the drug Wegovy – is scheduled to end in a number of nations in 2026. How Obesity Injections Work GLP-1 drugs mimick a natural hormone to reduce digestion speed, reduce hunger and enhance feelings of fullness so individuals reduce food intake. People commonly begin shedding pounds within a few weeks of starting on the once-weekly jabs. Research indicates users may regain a significant portion a year later of halting the treatment, as their typical hunger return. To be carrying excess weight raises your likelihood for developing health problems, such as diabetes, cardiovascular issues, stroke, and certain cancers. Excess weight affects individuals in all nations and was responsible for 3.7 million deaths worldwide in 2024, according to the WHO.
Less than 10% of patients who could benefit from GLP-1 drugs like Wegovy have access to them, warns the World Health Organization as it publishes its initial guidance on the therapies. Given over a billion individuals worldwide currently obese, it is advocating for increased and just availability to these injectable treatments. According to projections, over two billion will be obese by 2030 if no action is taken. "Our new guidelines acknowledges that excess weight is a chronic disease that can be managed with thorough and ongoing treatment," remarked its chief Tedros Adhanom Ghebreyesus. High costs, insufficient output, and supply-chain constraints are major hurdles to universal availability to the treatments that can help people shift substantial weight, explains the body. Skinny Jab Supply Crisis Even under the present most favorable outlook, the production of these medications might only reach about 100 million people – fewer than 10% of those who need them, as stated by the WHO. The advice urges nations and manufacturers to expand access, by strategies including patent sharing. The intellectual property rights on semaglutide – the primary component of the drug Wegovy – is scheduled to end in a number of nations in 2026. How Obesity Injections Work GLP-1 drugs mimick a natural hormone to reduce digestion speed, reduce hunger and enhance feelings of fullness so individuals reduce food intake. People commonly begin shedding pounds within a few weeks of starting on the once-weekly jabs. Research indicates users may regain a significant portion a year later of halting the treatment, as their typical hunger return. To be carrying excess weight raises your likelihood for developing health problems, such as diabetes, cardiovascular issues, stroke, and certain cancers. Excess weight affects individuals in all nations and was responsible for 3.7 million deaths worldwide in 2024, according to the WHO.